Indoco Remedies · NSE: INDOCO · BSE: 532612
Q1 FY25 results · Apr–Jun 2024
Indoco Remedies reported revenue from operations of ₹431.49 crore (up 1.2% from Q1 FY24) and net profit of ₹1.82 crore (down 92.5% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 431.49 | 426.50 | +1.2% | 449.64 | −4.0% |
| Other income | 1.03 | 0.41 | +151.2% | 2.66 | −61.3% |
| Total income | 432.52 | 426.91 | +1.3% | 452.30 | −4.4% |
| Profit before tax | 6.97 | 33.91 | −79.4% | 32.98 | −78.9% |
| Net profit for the period | 1.82 | 24.18 | −92.5% | 22.03 | −91.7% |
| Attributable to shareholders of the company | 2.62 | 24.39 | −89.3% | 22.70 | −88.5% |
| EPS, basic (₹) | 0.20 | 2.62 | −92.4% | 2.39 | −91.6% |
| Net margin (%) | 0.4 | 5.7 | 4.9 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 401.43 | 422.88 | −5.1% | 445.49 | −9.9% |
| Other income | 3.52 | 0.41 | +758.5% | 4.05 | −13.1% |
| Total income | 404.95 | 423.29 | −4.3% | 449.54 | −9.9% |
| Profit before tax | 19.51 | 35.67 | −45.3% | 46.50 | −58.0% |
| Net profit for the period | 14.95 | 25.94 | −42.4% | 37.56 | −60.2% |
| EPS, basic (₹) | 1.62 | 2.81 | −42.3% | 4.08 | −60.3% |
| Net margin (%) | 3.7 | 6.1 | 8.4 |
Consolidated
- Filed with BSE
- 24 Jul 2024, 09:36 IST
- Board meeting
- 23 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Jul 2024, 09:36 IST
- Board meeting
- 23 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE